Credit Suisse Ag Exact Sciences Corp Transaction History

Credit Suisse Ag

$101 Billion
Q1 2024

A detailed history of Credit Suisse Ag transactions in Exact Sciences Corp stock. As of the latest transaction made, Credit Suisse Ag holds 976,932 shares of EXAS stock, worth $56.8 Million. This represents 0.07% of its overall portfolio holdings.

Number of Shares

976,932

Previous 989,644 1.28%

Holding current value

$56.8 Million

Previous $73.2 Million 7.85%

% of portfolio

0.07%

Previous 0.07%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$56.27 - $73.77 $715,304 - $937,764	-12,712 Reduced 1.28%	976,932 $67.5 Million
Q4 2023 Feb 08, 2024	BUY	$59.06 - $75.72 $122,077 - $156,513	2,067 Added 0.21%	989,644 $73.2 Million
Q3 2023 Nov 13, 2023	BUY	$65.94 - $99.04 $2.08 Million - $3.13 Million	31,585 Added 3.3%	987,577 $67.4 Million
Q2 2023 Aug 11, 2023	SELL	$62.68 - $95.05 $12.8 Million - $19.3 Million	-203,534 Reduced 17.55%	955,992 $89.8 Million
Q1 2023 May 10, 2023	SELL	$47.19 - $70.77 $19.2 Million - $28.8 Million	-406,956 Reduced 25.98%	1,159,526 $78.6 Million
Q4 2022 Feb 13, 2023	SELL	$30.35 - $53.15 $464,233 - $812,982	-15,296 Reduced 0.97%	1,566,482 $77.6 Million
Q3 2022 Nov 10, 2022	BUY	$31.97 - $49.37 $145,911 - $225,324	4,564 Added 0.29%	1,581,778 $51.4 Million
Q2 2022 Aug 12, 2022	BUY	$35.61 - $76.23 $136,884 - $293,028	3,844 Added 0.24%	1,577,214 $62.1 Million
Q1 2022 May 16, 2022	SELL	$57.56 - $82.54 $30 Million - $43 Million	-521,297 Reduced 24.89%	1,573,370 $110 Million
Q4 2021 Feb 14, 2022	SELL	$72.5 - $100.68 $2.92 Million - $4.05 Million	-40,229 Reduced 1.88%	2,094,667 $163 Million
Q3 2021 Nov 12, 2021	BUY	$90.24 - $124.05 $22.4 Million - $30.9 Million	248,728 Added 13.19%	2,134,896 $204 Million
Q2 2021 Aug 16, 2021	BUY	$93.66 - $139.27 $5.96 Million - $8.86 Million	63,634 Added 3.49%	1,886,168 $234 Million
Q1 2021 May 14, 2021	BUY	$116.57 - $155.01 $61.1 Million - $81.3 Million	524,476 Added 40.4%	1,822,534 $240 Million
Q4 2020 Feb 12, 2021	SELL	$99.61 - $142.12 $33.6 Million - $47.9 Million	-336,867 Reduced 20.6%	1,298,058 $172 Million
Q3 2020 Nov 13, 2020	BUY	$72.92 - $102.01 $25.7 Million - $36 Million	352,544 Added 27.49%	1,634,925 $167 Million
Q2 2020 Aug 12, 2020	SELL	$55.75 - $92.75 $17.4 Million - $29 Million	-312,135 Reduced 19.58%	1,282,381 $111 Million
Q1 2020 May 13, 2020	BUY	$37.9 - $104.44 $30.2 Million - $83.1 Million	795,849 Added 99.65%	1,594,516 $92.5 Million
Q4 2019 Feb 12, 2020	BUY	$77.66 - $99.74 $22 Million - $28.2 Million	283,153 Added 54.93%	798,667 $73.9 Million
Q3 2019 Nov 12, 2019	SELL	$90.37 - $122.49 $4.06 Million - $5.5 Million	-44,889 Reduced 8.01%	515,514 $46.6 Million
Q2 2019 Aug 14, 2019	SELL	$89.51 - $118.04 $10.8 Million - $14.3 Million	-120,817 Reduced 17.74%	560,403 $66.2 Million
Q1 2019 May 14, 2019	BUY	$61.98 - $96.5 $3.11 Million - $4.84 Million	50,164 Added 7.95%	681,220 $59 Million
Q4 2018 Feb 13, 2019	BUY	$56.04 - $82.66 $5.7 Million - $8.41 Million	101,730 Added 19.22%	631,056 $39.8 Million
Q3 2018 Nov 13, 2018	BUY	$48.29 - $80.6 $2.58 Million - $4.3 Million	53,356 Added 11.21%	529,326 $41.8 Million
Q2 2018 Aug 14, 2018	SELL	$37.84 - $69.96 $10.6 Million - $19.7 Million	-281,186 Reduced 37.14%	475,970 $28.5 Million
Q1 2018 May 15, 2018	BUY	$39.82 - $57.53 $12.2 Million - $17.6 Million	305,388 Added 67.6%	757,156 $30.5 Million
Q4 2017 Feb 14, 2018	BUY	$46.49 - $60.51 $11 Million - $14.3 Million	235,551 Added 108.94%	451,768 $23.7 Million
Q3 2017 Nov 14, 2017	SELL	$37.05 - $47.12 $701,171 - $891,746	-18,925 Reduced 8.05%	216,217 $10.2 Million
Q2 2017 Aug 14, 2017	BUY	N/A	235,142	235,142 $8.32 Million

Others Institutions Holding EXAS

# of Institutions

673

Shares Held

162M

Call Options Held

2.58M

Put Options Held

2.19M

View Full List

About EXACT SCIENCES CORP

Ticker EXAS
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 176,960,000
Market Cap $10.3B
Description
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...

More about EXAS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

News

Stay updated on Credit Suisse Ag with notifications on news.

Account